TY - JOUR
T1 - Meta-analysis of the relationship between Parkinson disease and melanoma
AU - Liu, Rui
AU - Gao, Xiang
AU - Lu, Yi
AU - Chen, Honglei
PY - 2011/6/7
Y1 - 2011/6/7
N2 - Objective: To assess the epidemiologic evidence on melanoma in relation to Parkinson disease (PD) via systematic review and meta-analysis. Methods: Epidemiologic studies on melanoma and PD were searched using PubMed, Web of Science, Scoups, and Embase (1965 through June 2010). Eligible studies were those that reported risk estimates of melanoma among patients with PD or vice versa. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results: We identified 12 eligible publications on melanoma and PD: 8 had fewer than 10 cases with both PD and melanoma, and 7 provided gender-specific results. The pooled OR was 2.11 (95% CI 1.26-3.54) overall, 2.04 (1.55-2.69) for men, and 1.52 (0.85-2.75) for women. Analyses by temporal relationship found that melanoma occurrence was significantly higher after the diagnosis of PD (OR 3.61, 95% CI 1.49-8.77), but not before PD diagnosis (OR 1.07, 95% CI 0.62-1.84). Further analyses revealed that the lack of significance in the latter analysis was due to one study, which when excluded resulted in a significant association (OR 1.44, 95% CI 1.06-1.96). We also analyzed nonmelanoma skin cancers in relation to PD and found no significant relationship (OR 1.11, 95% CI 0.94-1.30). Conclusions: Collective epidemiologic evidence supports an association of PD with melanoma. Further research is needed to examine the nature and mechanisms of this relationship. Glossary: CI: confidence intervalMeSH: medical subject headingOR: odds ratioPD: Parkinson diseaseRR: relative riskSIR/SER: standardized incidence/event ratio.
AB - Objective: To assess the epidemiologic evidence on melanoma in relation to Parkinson disease (PD) via systematic review and meta-analysis. Methods: Epidemiologic studies on melanoma and PD were searched using PubMed, Web of Science, Scoups, and Embase (1965 through June 2010). Eligible studies were those that reported risk estimates of melanoma among patients with PD or vice versa. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results: We identified 12 eligible publications on melanoma and PD: 8 had fewer than 10 cases with both PD and melanoma, and 7 provided gender-specific results. The pooled OR was 2.11 (95% CI 1.26-3.54) overall, 2.04 (1.55-2.69) for men, and 1.52 (0.85-2.75) for women. Analyses by temporal relationship found that melanoma occurrence was significantly higher after the diagnosis of PD (OR 3.61, 95% CI 1.49-8.77), but not before PD diagnosis (OR 1.07, 95% CI 0.62-1.84). Further analyses revealed that the lack of significance in the latter analysis was due to one study, which when excluded resulted in a significant association (OR 1.44, 95% CI 1.06-1.96). We also analyzed nonmelanoma skin cancers in relation to PD and found no significant relationship (OR 1.11, 95% CI 0.94-1.30). Conclusions: Collective epidemiologic evidence supports an association of PD with melanoma. Further research is needed to examine the nature and mechanisms of this relationship. Glossary: CI: confidence intervalMeSH: medical subject headingOR: odds ratioPD: Parkinson diseaseRR: relative riskSIR/SER: standardized incidence/event ratio.
UR - http://www.scopus.com/inward/record.url?scp=79958696375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958696375&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31821e554e
DO - 10.1212/WNL.0b013e31821e554e
M3 - Article
C2 - 21646627
AN - SCOPUS:79958696375
SN - 0028-3878
VL - 76
SP - 2002
EP - 2009
JO - Neurology
JF - Neurology
IS - 23
ER -